Funding News Edition: March 20, 2019 See more articles in this edition
Could your research lead to a novel multipurpose prevention technology (MPT) that can simultaneously prevent HIV infection and pregnancy; sexually transmitted infections (STIs) and pregnancy; or multiple non-HIV STIs? If so, consider applying for funding through the new funding opportunity announcement (FOA) Next Generation Multipurpose Prevention Technologies (NGM) (R01, Clinical Trial Optional).
Proposed MPTs can be contraceptive or non-contraceptive, and may encompass a wide range of delivery durations and use patterns, e.g., on-demand, event-driven, or sustained/extended release. Ideally, your MPT will be optimized for use and uptake by cisgender and transgender males and females at high risk for HIV infection or STIs and pregnancy.
Within that broad parameter, NIAID is especially interested in research:
- Developing episodic dosed MPTs for use during periods of sexual activity with at least seven days protection from a single dose
- Developing sustained/extended release MPTs that provide months to years of protection from HIV infections or STIs and pregnancy
- Developing animal models that evaluate the efficacy and safety of an MPT product’s active ingredients
- Identifying and assessing drug to drug interactions that could compromise MPT safety and effectiveness
- Understanding the pharmacokinetics and pharmacodynamics of all drugs in the MPT products
- Developing MPTs that deliver effective HIV drug concentrations to both the female reproductive tract and gastrointestinal tract of males and females
- Understanding the biobehavioral factors that govern decisions made by individuals to use or not use MPTs, and how these decisions can influence the rheological and biophysical properties (look, feel, and duration) of the MPT
Your research proposal should include milestones and timelines for developing the proposed MPT. If biobehavioral research is proposed, outcomes should include optimizing the rheological and biophysical properties of the proposed MPT to increase product uptake by the target population(s).
Through this FOA, NIAID will not support:
- Developing a product that is not an MPT, e.g., one with a single indication or target organism
- Clinical trials (Phase I, II, or III and exploratory investigational new drug) proposing dosing of an MPT; NIAID will limit clinical trial research to biobehavioral studies that meet NIH's Definition of a Clinical Trial.
- MPT strategies composed of HIV or STI vaccines
- Use of live biotherapeutics or vectored biotherapeutics to deliver the anti-HIV component of an MPT
This FOA has three deadlines to apply: May 6, 2019; May 6, 2020; and May 6, 2021.
Your budget request is not limited but should reflect the actual needs of your proposed project. If you plan to request more than $500,000 in direct costs in any one year, follow the preapproval process explained in our Big Grants SOP. Your proposed project period cannot exceed five years.
Read the FOA linked above for complete details. If you are developing an application to address NIAID’s specific interests, send any questions to Dr. Jim Turpin.